Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Cancer Survivors in the United States  
  • Because of advances in treatment, the 5-year survival rate for people with actue lymphocytic leukemia has increased from 38% in 1974-1976 to 65% in 1995-2001.  
  • Cancer death rates for all races/ethnicities and both sexes combined decreased by 2.1% per year from 2002-2004, nearly twice the annual decrease of 1.1% per year from 1993-2002.  
  • Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient.   
  • Between 2008 and 2010, use of colonoscopy for the treatment and prevention of colon cancer saved an average of $150,364 each year, per person affected.